Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Colorectal Neoplasms

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    November 2025
  1. LV M, Hu C, Li J, Zhang Y, et al
    Serotonin receptor type 7 (5-HT7) promotes colorectal cancer progression by activating Wnt/beta-catenin signaling via interacting with CK1epsilon.
    Oncogene. 2025 Nov 26. doi: 10.1038/s41388-025-03645.
    PubMed     Abstract available


  2. SMABERS LP, Nienhuis HH, de Leng WWJ, Roepman P, et al
    Clinical implications of whole genome sequencing in metastatic colorectal cancer.
    Oncogene. 2025 Nov 7. doi: 10.1038/s41388-025-03618.
    PubMed     Abstract available


    October 2025
  3. HU Y, Liu W, Qiang D, Huang K, et al
    Emerging roles of RNA-binding protein hnRNPM in alternative splicing regulation and UTMD mediated sh-hnRNPM/CMBs suppress the proliferation of colorectal cancer.
    Oncogene. 2025 Oct 19. doi: 10.1038/s41388-025-03599.
    PubMed     Abstract available


  4. HUANG M, Qin B, Xie Z, Zhou R, et al
    Publisher Correction: RCN3 functions as a tumor promoter in colorectal cancer by modulating the GRP78-PI3K-AKT signaling pathway.
    Oncogene. 2025 Oct 8. doi: 10.1038/s41388-025-03592.
    PubMed    


  5. LANZLOTH R, Harris NL, Cannon AM, Kaplan MH, et al
    Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition.
    Oncogene. 2025 Oct 2. doi: 10.1038/s41388-025-03589.
    PubMed     Abstract available


    September 2025
  6. LIN P, Lin C, Teng Z, Liu S, et al
    USP10-mediated Ku70/80 stabilization inhibits PANoptosis and promotes chemoresistance in colorectal cancer.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03570.
    PubMed     Abstract available


  7. YIN Y, Ming L, Qin Y, Tang J, et al
    RAB22A triggers intercellular chemoresistance transmission in colorectal cancer by promoting exosome release via the PKM2-pSNAP23 axis.
    Oncogene. 2025 Sep 16. doi: 10.1038/s41388-025-03566.
    PubMed     Abstract available


  8. REN Y, Chen J, Zhan X, Sheng S, et al
    Correction: Liquid-liquid phase separation of GPS2-LATS1 promotes colorectal cancer progression by reprogramming lipid metabolism.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03540.
    PubMed    


  9. TRAN TQ, Duysak T, Kim K, Dang GC, et al
    Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella.
    Oncogene. 2025;44:3449-3460.
    PubMed     Abstract available


    August 2025
  10. STRELEZ C, Battaglin F, Perez R, Yang Y, et al
    GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer.
    Oncogene. 2025 Aug 24. doi: 10.1038/s41388-025-03546.
    PubMed     Abstract available


  11. HUANG M, Qin B, Xie Z, Zhou R, et al
    RCN3 functions as a tumor promoter in colorectal cancer by modulating the GRP78-PI3K-AKT signaling pathway.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03535.
    PubMed     Abstract available


  12. WANG YN, Zeng ZL, Lu J, Wang Y, et al
    Correction: CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis.
    Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03508.
    PubMed    


  13. IDEN JA, Ben-Califa N, Naim A, Liron T, et al
    Immunomodulatory function of cannabinoid receptor 2 and its agonist osteogenic growth peptide in health and cancer: a study in mice and humans.
    Oncogene. 2025;44:2504-2514.
    PubMed     Abstract available


    July 2025
  14. REN Y, Chen J, Zhan X, Sheng S, et al
    Liquid-liquid phase separation of GPS2-LATS1 promotes colorectal cancer progression by reprogramming lipid metabolism.
    Oncogene. 2025 Jul 25. doi: 10.1038/s41388-025-03498.
    PubMed     Abstract available


  15. TARRADO-CASTELLARNAU M, Foguet C, Tarrago-Celada J, Palobart M, et al
    Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells.
    Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03495.
    PubMed     Abstract available


  16. CONG B, Thakur T, Uribe AH, Stamou E, et al
    Colon cancer cells evade drug action by enhancing drug metabolism.
    Oncogene. 2025 Jul 10. doi: 10.1038/s41388-025-03472.
    PubMed     Abstract available


  17. HAN H, Li Y, Lin Z, Ma X, et al
    ALKBH5 suppresses m(6)A mRNA modification of FOXM1 to drive Cetuximab resistance in KRAS-mutant colorectal cancer.
    Oncogene. 2025 Jul 7. doi: 10.1038/s41388-025-03490.
    PubMed     Abstract available


  18. JAYACHANDRAN P, Elliott A, Soni S, Battaglin F, et al
    Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.
    Oncogene. 2025 Jul 4. doi: 10.1038/s41388-025-03484.
    PubMed     Abstract available


  19. ZHAO M, Nie J, Ye A, Liu C, et al
    Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer.
    Oncogene. 2025 Jul 3. doi: 10.1038/s41388-025-03488.
    PubMed     Abstract available


    June 2025
  20. WU H, Hu X, Wang Y, Zhu X, et al
    RBM5 recruiting MGC32805 in a sandwich mode and inducing DeltaFAS neoantigen and triggering FAS properties switch: implication in colorectal cancer.
    Oncogene. 2025 Jun 26. doi: 10.1038/s41388-025-03390.
    PubMed     Abstract available


  21. GUO ST, Jiang CC, Wang GP, Li YP, et al
    Correction: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
    Oncogene. 2025 Jun 3. doi: 10.1038/s41388-025-03446.
    PubMed    


  22. GU J, Xu X, Li X, Yue L, et al
    Correction: Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation.
    Oncogene. 2025 Jun 2. doi: 10.1038/s41388-025-03439.
    PubMed    


  23. BAI X, Duan T, Shao J, Zhang Y, et al
    CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis.
    Oncogene. 2025;44:1678-1693.
    PubMed     Abstract available


    May 2025
  24. QU S, Feng B, Xing M, Qiu Y, et al
    PRMT5 K240lac confers ferroptosis resistance via ALKBH5/SLC7A11 axis in colorectal cancer.
    Oncogene. 2025 May 30. doi: 10.1038/s41388-025-03457.
    PubMed     Abstract available


  25. PAN D, Hu J, Li G, Gao X, et al
    BRD4 regulates PAI-1 expression in tumor-associated macrophages to drive chemoresistance in colorectal cancer.
    Oncogene. 2025 May 28. doi: 10.1038/s41388-025-03453.
    PubMed     Abstract available


    April 2025
  26. WOUTERS VM, Helderman RFCPA, Cameron K, van der Hooff SR, et al
    CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer.
    Oncogene. 2025 Apr 6. doi: 10.1038/s41388-025-03365.
    PubMed     Abstract available


    March 2025
  27. TAIRA A, Aavikko M, Katainen R, Kaasinen E, et al
    Comprehensive metabolomic and epigenomic characterization of microsatellite stable BRAF-mutated colorectal cancer.
    Oncogene. 2025 Mar 18. doi: 10.1038/s41388-025-03326.
    PubMed     Abstract available


  28. WANG B, Zhang S, Guo Y, Gao W, et al
    CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis.
    Oncogene. 2025 Mar 13. doi: 10.1038/s41388-025-03331.
    PubMed     Abstract available


    February 2025
  29. SHENG Z, Luo S, Huang L, Deng YN, et al
    SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis.
    Oncogene. 2025 Feb 23. doi: 10.1038/s41388-025-03302.
    PubMed     Abstract available


  30. YAN Z, He L, Yuan J, Niu Y, et al
    The splicing factor SRRM2 modulates two S6K kinases to promote colorectal cancer growth.
    Oncogene. 2025 Feb 16. doi: 10.1038/s41388-025-03307.
    PubMed     Abstract available


  31. ZHANG J, Zhai J, Wong CC, Chen H, et al
    Correction: A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML).
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-025-03304.
    PubMed    


  32. RUAN DY, Li T, Wang YN, Meng Q, et al
    Correction: FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.
    Oncogene. 2025 Feb 4. doi: 10.1038/s41388-025-03287.
    PubMed    


    January 2025
  33. REISSLAND M, Hartmann O, Tauch S, Bugter JM, et al
    Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.
    Oncogene. 2025 Jan 22. doi: 10.1038/s41388-024-03262.
    PubMed    


    December 2024
  34. LIAO Y, Yang R, Wang B, Ruan Y, et al
    Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer.
    Oncogene. 2024 Dec 26. doi: 10.1038/s41388-024-03255.
    PubMed     Abstract available


    November 2024
  35. ZHUANG M, Liu J, Li Y, Zhang J, et al
    PD-L1 promotes tumor metastasis by regulating the infiltration of FGFBP2(+)Tm cells in colorectal cancer.
    Oncogene. 2024 Nov 18. doi: 10.1038/s41388-024-03223.
    PubMed     Abstract available


  36. WEN M, Qiu Y, Wang M, Tang F, et al
    Enhancing low-dose radiotherapy efficacy with PARP inhibitors via FBL-mediated oxidative stress response in colorectal cancer.
    Oncogene. 2024 Nov 8. doi: 10.1038/s41388-024-03207.
    PubMed     Abstract available


  37. DUYSAK T, Kim K, Yun M, Jeong JH, et al
    Enhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum.
    Oncogene. 2024;43:3378-3387.
    PubMed     Abstract available


  38. BORDONE R, Ivy DM, D'Amico R, Barba M, et al
    MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation.
    Oncogene. 2024;43:3349-3365.
    PubMed     Abstract available


    October 2024
  39. BORDING T, Janik T, Bischoff P, Morkel M, et al
    GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy.
    Oncogene. 2024 Oct 29. doi: 10.1038/s41388-024-03200.
    PubMed     Abstract available


  40. REISSLAND M, Hartmann O, Tauch S, Bugter JM, et al
    USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.
    Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03141.
    PubMed     Abstract available


  41. LIN W, Xu L, Li Y, Li J, et al
    Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing.
    Oncogene. 2024 Oct 13. doi: 10.1038/s41388-024-03189.
    PubMed     Abstract available


  42. HAN F, Zhou X, Liu L, Yang B, et al
    GLTSCR1 deficiency promotes colorectal cancer development through regulating non-homologous end joining.
    Oncogene. 2024 Oct 11. doi: 10.1038/s41388-024-03179.
    PubMed     Abstract available


    September 2024
  43. XU H, Wang T, Nie H, Sun Q, et al
    USP36 promotes colorectal cancer progression through inhibition of p53 signaling pathway via stabilizing RBM28.
    Oncogene. 2024 Sep 29. doi: 10.1038/s41388-024-03178.
    PubMed     Abstract available


  44. SUN Z, Dang P, Guo Y, Liu S, et al
    Targeting CircAURKA prevents colorectal cancer progression via enhancing CTNNB1 protein degradation.
    Oncogene. 2024 Sep 28. doi: 10.1038/s41388-024-03155.
    PubMed     Abstract available


  45. TANG W, Yang Y, Fu Z, Xu W, et al
    The RNA helicase DDX21 activates YAP to promote tumorigenesis and is transcriptionally upregulated by beta-catenin in colorectal cancer.
    Oncogene. 2024 Sep 17. doi: 10.1038/s41388-024-03160.
    PubMed     Abstract available


  46. CHURCHHOUSE AMD, Billard CV, Suzuki T, Pohl SOG, et al
    Loss of DOCK2 potentiates Inflammatory Bowel Disease-associated colorectal cancer via immune dysfunction and IFNgamma induction of IDO1 expression.
    Oncogene. 2024 Sep 7. doi: 10.1038/s41388-024-03135.
    PubMed     Abstract available


    August 2024
  47. GUPTA A, Avadhanula S, Bashyam MD
    Evaluation of the gene fusion landscape in early onset sporadic rectal cancer reveals association with chromatin architecture and genome stability.
    Oncogene. 2024;43:2449-2462.
    PubMed     Abstract available


    July 2024
  48. LI X, Chen Y, Lu R, Hu M, et al
    Correction: Colorectal cancer cells secreting DKK4 transform fibroblasts to promote tumour metastasis.
    Oncogene. 2024 Jul 15. doi: 10.1038/s41388-024-03101.
    PubMed    


    June 2024
  49. GU J, Xu X, Li X, Yue L, et al
    Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation.
    Oncogene. 2024 Jun 18. doi: 10.1038/s41388-024-03080.
    PubMed     Abstract available


  50. FENG M, Chai C, Hao X, Lai X, et al
    Inherited KDM6A(A649T) facilitates tumor-immune escape and exacerbates colorectal signet-ring cell carcinoma outcomes.
    Oncogene. 2024;43:1757-1768.
    PubMed     Abstract available


    April 2024
  51. CAO N, Zhang F, Yin J, Zhang J, et al
    LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis.
    Oncogene. 2024 Apr 11. doi: 10.1038/s41388-024-02996.
    PubMed     Abstract available


  52. WU Q, Wang Z, Chen S, She X, et al
    USP26 promotes colorectal cancer tumorigenesis by restraining PRKN-mediated mitophagy.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03009.
    PubMed     Abstract available


    March 2024
  53. LI X, Chen Y, Lu R, Hu M, et al
    Colorectal cancer cells secreting DKK4 transform fibroblasts to promote tumour metastasis.
    Oncogene. 2024 Mar 22. doi: 10.1038/s41388-024-03008.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.